高乌甲素固体分散体单层渗透泵和高乌甲素双层渗透泵的制备及体外释药行为研究

doi:10.5246/jcps.2017.06.045

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (6): 413-422.DOI: 10.5246/jcps.2017.06.045

高乌甲素固体分散体单层渗透泵和高乌甲素双层渗透泵的制备及体外释药行为研究

吴先闯¹, 王姣姣², 郝海军^2*, 宋晓勇^1*, 张永州¹, 刘瑜新¹, 张红芹³

1. 河南大学淮河医院药学部, 河南开封 475000
2. 上海医药工业研究院, 上海 201203
3. 上海艾韦特医药科技有限公司, 上海 201203

收稿日期:2017-02-15 修回日期:2017-04-20 出版日期:2017-06-29 发布日期:2017-04-25
通讯作者: Tel.: +86-021-50272000-1041; +86-0371-23906970, E-mail: haohj2007@126.com; sxyyjk@sina.com
基金资助:
Science and Technology Department of Henan Province Fund Project (Grant No. 144300510019).

Lappaconitine solid dispersion monolithic osmotic tablet and lappaconitine push-pull osmotic pump: preparation and comparison of their release performance in vitro

Xianchuang Wu¹, Jiaojiao Wang², Haijun Hao^2*, Xiaoyong Song^1*, Yongzhou Zhang¹, Yuxin Liu¹, Hongqin Zhang³

1. Department of Pharmacy, Huai He Hospital of Henan University, Kaifeng 475000
2. Shanghai Institute of Pharmaceutical Industry, Shanghai 200437
3. Shanghai Advanced Vehicle Technology Pharmaceutical L.T.D. Co, Shanghai 201203

Received:2017-02-15 Revised:2017-04-20 Online:2017-06-29 Published:2017-04-25
Contact: Tel.: +86-021-50272000-1041; +86-0371-23906970, E-mail: haohj2007@126.com; sxyyjk@sina.com
Supported by:
Science and Technology Department of Henan Province Fund Project (Grant No. 144300510019).

摘要/Abstract

摘要：

高乌甲素水溶性较差, 作为本研究模型药, 对难溶性药物来说, 目前主要采用单层渗透泵和双层渗透泵两种控释技术来制备渗透控释制剂。本研究分别制备了高乌甲素固体分散体单层渗透泵和高乌甲素双层渗透泵。高乌甲素双层渗透泵控释片可以近似零级释药速率进行释药(r = 0.9931), 累积释放度达到95.0%。而高乌甲素固体分散体单层渗透泵控释片与高乌甲素双层渗透泵相比(r = 0.9931)零级释药特征相对较差(r = 0.9798), 累积释放度为84.69%。因此, 高乌甲素双层渗透泵与高乌甲素固体分散体单层渗透泵相比, 在控制药物释放方面更具优势(更高的零级释放拟合度)。高乌甲素双层渗透泵和高乌甲素固体分散体单层渗透泵相似因子f₂为49.1(<50.0), 两种渗透泵控释制剂体外释放特征明显不同。高乌甲素双层渗透泵零级释药效果优于高乌甲素固体分散体单层渗透泵, 且累积释放度也较高。因此, 双层渗透泵技术在控制难溶性药物释放方面比单层渗透泵更具优势, 但制备过程较为复杂。

关键词: 高乌甲素, 固体分散体, 单层渗透泵, 双层渗透泵

Abstract:

Lappaconitine is a water-insoluble drug, which was used as model drug in this study. Currently, two osmotically controlleddelivery systems that are widely used for water-insoluble drug are monolithic osmotic tablet (MOT) and push–pull osmotic pump (PPOP). In the present study, lappaconitine solid dispersion monolithic osmotic tablet (lappaconitine-SD-MOT) and lappaconitine-PPOP were developed. The prepared lappaconitine-PPOP was able to delivery drug at the rate of approximate zero-order (r = 0.9931), and the cumulative release was above 95.0%. The lappaconitine-SD-MOT showed a comparatively poor linearity when the data were plotted according to the zero-order equation (r = 0.9798), and the cumulative release was 84.69%. Lappaconitine-PPOP exhibited better controlled drug release (higher regression value) compared with lappaconitine-SD-MOT. The similarity index (f₂) between lappaconitine-PPOP and lappaconitine-SD-MOT was 49.1 (<50). A clear difference of drug release characteristics between the lappaconitine-SD-MOT and lappaconitine-PPOP was revealed. It indicated that the drug release performance of lappaconitine-PPOPcould gain favorable zero-order kinetics and higher cumulative release compared with lappaconitine-SD-MOT. Therefore, these results suggested that PPOP was still a very effective device for the delivery of poorly water-soluble drug with zero-order pattern.

Key words: Lappaconitine, Solid dispersion, Monolithic osmotic tablet, Push-pull osmotic pumps

中图分类号:

R943

Supporting:

吴先闯, 王姣姣, 郝海军, 宋晓勇, 张永州, 刘瑜新, 张红芹. 高乌甲素固体分散体单层渗透泵和高乌甲素双层渗透泵的制备及体外释药行为研究[J]. 中国药学(英文版), 2017, 26(6): 413-422.

Xianchuang Wu, Jiaojiao Wang, Haijun Hao, Xiaoyong Song, Yongzhou Zhang, Yuxin Liu, Hongqin Zhang. Lappaconitine solid dispersion monolithic osmotic tablet and lappaconitine push-pull osmotic pump: preparation and comparison of their release performance in vitro[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(6): 413-422.

参考文献

[1] Wang, Y.Z.; Xiao, Y.Q.; Zhang, C.; Sun X.M. J. Tradit. Chin. Med. 2009, 29, 141–145.

[2] Huang, Y.B.; Tsai, Y.H.; Yang, W.C.; Chang, J.S.; Wu, P.C.; Takayama, K. Eur. J. Pharm. Biopharm. 2004, 58, 607–614.

[3] Liu, L.; Wang, X. Eur. J. Pharm. Biopharm. 2008, 68, 298–302.

[4] Bhanushali, R.; Wakode, R.; Bajaj, A. J. Pharm. Innov. 2009, 4, 63–70.

[5] Guan, J.; Zhou, L.; Nie, S.; Yan, T.; Tang, X.; Pan, W. Int. J. Pharm. 2010, 383, 30–36.

[6] Theeuwes, F. J. Pharm. Sci. 1975, 64, 1987–1991.

[7] Prabakaran, D.; Singh, P.; Kanaujia, P.; Jaganathan, K.S.; Rawat, A.; Vyas, S.P. Int. J. Pharm. 2004, 284, 95–108.

[8] Malaterre, V.; Ogorka, J.; Loggia, N.; Gurny, R. Int. J. Pharm. 2009, 376, 56–62.

[9] Liu, L.; Khang, G.; Rhee, J.M.; Lee, H.B. J. Controlled. Release. 2000, 67, 309–322.

[10] Waterman, K.C.; Macdonald, B.C.; Roy, M.C. J. Controlled. Release. 2009, 134, 201–206.

[11] Liu, L.; Wang, X. Eur. J. Pharm. Biopharm. 2008, 68, 298–302.

[12] Lu, E.; Jiang, Z.; Zhang, Q.; Jiang, X. J. Controlled. Release. 2003, 92, 375–382.

[13] Bhanushali, R.; Wakode, R.; Bajaj, A. J. Pharm. Innov. 2009, 4, 63–70.

[14] Roul, L.; Manna, N.; Parhi, R.; Sahoo, S.; Suresh, P. Indian J. Pharm. Educ. Res. 2012, 46, 38–44.

[15] Mohammadi, G.; Barzegar-Jalali, M.; Valizadeh, H.; Nazemiyeh, H.; Barzegar-Jalali, A.; Siahi Shadbad, M.R.; Adibkia, K.; Zare, M. J. Pharm. Pharm. Sci. 2010, 13, 152–161.

[16] Wu, X.C.; Hao, H.J.; Liu ,Y.X.; Song, X.Y.; Zhang, Y.Z.; Zhang, H.Q. J. Chin. Pharm. Sci. 2015, 24, 779–787.

[17] Jagdale, S.C.; Jadhav, V.N.; Chabukswar, A.R.; Kuchekar, B.S. Braz. J. Pharm. Sci. 2012, 48, 131–145.

[18] Liu, D.; Pan, H.; He, F.; Wang, X.; Li, J.; Yang, X.; Pan, W. Int. J. Nanomedicine. 2015, 13, 6425–6434.

[19] Chen, H.H.; Jiang, G.Q.; Ding, F.X. Drug Dev. Ind. Pharm. 2009, 35, 131–137.

[20] He, H.W.; Yan, F. Anal Sci. 2012, 28, 1203–1205.

[21] Hao, H.J.; Jia, Y.Z.; Zhang, H.Q.; Han, R.; Wang, X.P.; Han, L.M.; Wang, J.X. J. Chin. Pharm. Sci. 2015, 24, 383–392.

高乌甲素固体分散体单层渗透泵和高乌甲素双层渗透泵的制备及体外释药行为研究

Lappaconitine solid dispersion monolithic osmotic tablet and lappaconitine push-pull osmotic pump: preparation and comparison of their release performance in vitro

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高美琪, 吴佳丽, 朱文静, 张晓彤, 樊文玲. 利用热熔挤出技术制备和表征白藜芦醇缓释固体分散体[J]. 中国药学(英文版), 2023, 32(3): 165-179.
[2]	樊文玲, 徐艳, 张心怡, 狄留庆, 李磊. 三元固体分散体提高利多卡因溶解度研究[J]. 中国药学(英文版), 2020, 29(1): 55-65.
[3]	刘蒸生, 郝海军, 范明松. 槲皮素磷脂复合物固体分散体和固体分散体的制备及评价[J]. 中国药学(英文版), 2019, 28(12): 868-877.
[4]	程士轩, 马迎聪, 刘瑜洁, 庞宁, 李骥, 沙勐, 任汝通, Nuramatjan Ablat, 曹静, 孙懿, 蒲小平, 叶敏, 齐宪荣. 红花抗帕金森病有效成分滴丸的制备和表征[J]. 中国药学(英文版), 2019, 28(1): 27-39.
[5]	郝海军, 贾幼智, 张红芹, 韩茹, 王雪萍, 韩丽妹, 王建新. 槲皮素固体分散体单层渗透泵片的研制[J]. 中国药学(英文版), 2015, 24(6): 383-392.
[6]	吴先闯, 郝海军, 刘瑜新, 宋晓勇, 张永州, 张红芹. 羟基喜树碱磷脂复合物固体分散体和油制剂生物利用度的比较[J]. 中国药学(英文版), 2015, 24(12): 780-788.
[7]	马维娜, 谷福根, 王毅, 孟根达来, 吴春芝. 羟丙基-β-环糊精对水难溶性药物利培酮的包合及促溶作用[J]. 中国药学(英文版), 2015, 24(1): 47-53.
[8]	宋文丁, 杜若, 宋平, 钟婷, 张卫强, 赵阳, 王超, 张烜, 张强. 非布索坦二氧化硅固体分散体的制备及表征[J]. 中国药学(英文版), 2014, 23(7): 463-470.
[9]	马燕^*, 李卫中, 古锦辉. 难溶性药物水飞蓟宾固体分散体的制备及评价[J]. , 2011, 20(6): 604-608.
[10]	唐宁, 赖捷, 陈雅聘, 卢懿^, 吴伟^. 流化床法制备的非诺贝特固体分散体小丸: 物理表征、改善溶出和犬口服生物利用度[J]. , 2009, 18(2): 156-161.
[11]	孙葭北, 刘祥瑞, 王坚成, 吕万良, 张烜*, 张强. 紫杉醇-PVP固体分散体的制备、物相鉴定及细胞药效 [J]. , 2008, 17(2): 113-117.
[12]	刘祥瑞, 吴科春, 张春晖, 张烜^*, 张强 . 反相高效液相色谱法测定紫杉醇固体分散体中紫杉醇的含量[J]. , 2007, 16(2): 101-104.
[13]	朱静, 杨照罡, 陈晓梅, 孙葭北, 古丽斯坦·阿吾提, 张烜^*, 张强. 槲皮素PVP固体分散体的制备及物相鉴定[J]. , 2007, 16(1): 51-56.
[14]	魏振平, 毛世瑞, 毕殿洲, 李勇*. 西沙必利-HPMC固体分散体对其体外药物释放的促进作用[J]. , 2004, 13(4): 254-258.
[15]	郭圣荣^*, 郭丽. PVP K30对葛根黄豆苷元溶解度和溶出的影响[J]. , 2004, 13(1): 42-48.